

EXPLANATORY STATEMENT
NATIONAL HEALTH ACT 1953
NATIONAL HEALTH (EFFICIENT FUNDING OF CHEMOTHERAPY) SPECIAL
ARRANGEMENT AMENDMENT INSTRUMENT 2012 (No. 3)

PB 32 of 2012

Authority

Subsection 100(1) of the National Health Act 1953 (the Act) enables the Minister to make special arrangements for the supply of pharmaceutical benefits. Subsection 100(2) of the Act provides that the Minister may vary or revoke a special arrangement made under subsection 100(1).

Subsection 100(3) of the Act provides that Part VII of the Act, and instruments made for the purposes of Part VII have effect subject to a special arrangement made under subsection 100(1).

Purpose

The purpose of this legislative instrument, made under subsections 100(1) and 100(2) of the Act, is to amend the National Health (Efficient Funding of Chemotherapy) Special Arrangement 2011 (PB 79 of 2011) (the Special Arrangement), to make changes to the special arrangement relating to the efficient funding of chemotherapy.

The Special Arrangement achieves greater efficiency in payment for the supply of injected or infused chemotherapy medicines (“chemotherapy pharmaceutical benefits”) to eligible patients being treated for cancer, to reflect the 2010 budget measure titled ‘Revised arrangements for the efficient funding of chemotherapy drugs’. This special arrangement also relates to the supply of medicines associated with the side-effects of cancer and cancer treatment (“related pharmaceutical benefits”) at certain public hospitals.

This instrument makes changes to the pharmaceutical benefits available under the section 100 special arrangement for the efficient funding of chemotherapy. These changes reflect changes to the National Health (Listing of Pharmaceutical Benefits) Instrument made under sections 84AF, 85, 85A, 88 and 101 of the Act, which commence on the same day.

This Instrument:

- adds 2 new listed brands with the listed drug ‘Doxorubicin - Pegylated Liposomal’;
- removes 10 listed brands with the listed drugs ‘Carboplatin’, ‘Doxorubicin’, ‘Epirubicin’, ‘Irinotecan’, ‘Mitozantrone’, ‘Oxaliplatin’, ‘Vincristine’ and ‘Ondansetron’; and
- removes 3 pharmaceutical items with the listed drugs ‘Cisplatin’, ‘Doxorubicin’ and ‘Mitozantrone’.

This instrument also adds details relevant to the special patient contribution for a listed brand with the listed drug ‘Bleomycin’. This reflects a change made to the *National Health (Price and Special Patient Contribution) Determination 2010* (PB 109 of 2010).

This instrument also removes the responsible person code ‘WA’ and associated responsible person from the Special Arrangement to reflect that with the removal of the listed brand ‘Winthrop Oxaliplatin’ with the listed drug ‘Oxaliplatin’ there are no pharmaceutical benefits available for supply under this Special Arrangement that have the responsible person code ‘WA’ associated with them.

Consultations

An ongoing and formal process of consultation in relation to matters relevant to this instrument includes the involvement of interested parties through the membership of the Pharmaceutical Benefits Advisory Committee (PBAC). PBAC is an independent expert body established by section 100A of the Act which makes recommendations to the Minister about which drugs and medicinal preparations should be available as pharmaceutical benefits.

PBAC members are appointed following nomination by prescribed organisations and associations from consumers, health economists, practising community pharmacists, general practitioners, clinical pharmacologists and specialists, with at least one member selected from each of those interests or professions. Remaining members are persons whom the Minister is satisfied have qualifications and experience in a field relevant to the functions of PBAC, and that would enable them to contribute meaningfully to the deliberations of PBAC. When recommending the listing of a medicine on the Pharmaceutical Benefits Scheme (PBS), PBAC takes into account the medical conditions for which the medicine has been approved for use in Australia, its clinical effectiveness, safety and cost-effectiveness compared with other treatments.

This Instrument commences on 1 May 2012.

This Instrument is a legislative instrument for the purposes of the *Legislative Instruments Act 2003*.

A provision by provision description of this Instrument is contained in the [Attachment](#).

***PROVISION BY PROVISION DESCRIPTION OF THE NATIONAL HEALTH
(EFFICIENT FUNDING OF CHEMOTHERAPY) SPECIAL ARRANGEMENT
AMENDMENT INSTRUMENT 2012 (No. 3)***

Section 1 Name of Instrument

This section provides that this Instrument is the National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2012 (No. 3) and that it may also be cited as PB 32 of 2012.

Section 2 Commencement

This section provides that this Instrument commences on 1 May 2012.

Section 3 Amendments to PB 79 of 2011

This section provides that Schedule 1 amends the National Health (Efficient Funding of Chemotherapy) Special Arrangement 2011 (PB 79 of 2011) (the Special Arrangement).

Schedule 1

Item 1 amends the entry in Schedule 1 Part 1 of the Special Arrangement for ‘Carboplatin’ by removing a pharmaceutical benefit, which is the listed drug ‘Carboplatin’ in the form ‘Solution for I.V. injection 50 mg in 5 mL’ with manner of administration ‘Injection’ and brand ‘Pfizer Australia Pty Ltd’.

Item 2 amends the entry in Schedule 1 Part 1 of the Special Arrangement for ‘Cisplatin’ by removing a pharmaceutical benefit, which is the listed drug ‘Cisplatin’ in the form ‘I.V. injection 10 mg in 10 mL’ with manner of administration ‘Injection’ and brand ‘Pfizer Australia Pty Ltd’.

Item 3 amends the entry in Schedule 1 Part 1 of the Special Arrangement for ‘Doxorubicin’ by removing a pharmaceutical benefit, which is the listed drug ‘Doxorubicin’ in the form ‘Solution for I.V. injection or intravesical administration containing doxorubicin hydrochloride 10 mg in 5 mL single dose vial’ with manner of administration ‘Injection/ intravesical’ and brand ‘Adriamycin Solution’.

Item 4 amends the entry in Schedule 1 Part 1 of the Special Arrangement for ‘Doxorubicin’ by removing a pharmaceutical benefit, which is the listed drug ‘Doxorubicin’ in the form ‘Solution for I.V. injection or intravesical administration containing doxorubicin hydrochloride 20 mg in 10 mL single dose vial’ with manner of administration ‘Injection/ intravesical’ and brand ‘Adriamycin Solution’.

Item 5 amends the entry in Schedule 1 Part 1 of the Special Arrangement for ‘Doxorubicin - Pegylated Liposomal’ by adding a new pharmaceutical benefit, which is the listed drug ‘Doxorubicin - Pegylated Liposomal’ in the form ‘Suspension for I.V. infusion containing pegylated liposomal doxorubicin hydrochloride 20 mg in 10 mL’ with manner of administration ‘Injection’ and brand ‘Lipodox’.

Item 6 amends the entry in Schedule 1 Part 1 of the Special Arrangement for ‘Doxorubicin - Pegylated Liposomal’ by adding a new pharmaceutical benefit, which is the listed drug ‘Doxorubicin - Pegylated Liposomal’ in the form ‘Suspension for I.V. infusion containing pegylated liposomal doxorubicin hydrochloride 50 mg in 25 mL’ with manner of administration ‘Injection’ and brand ‘Lipodox 50’.

Item 7 amends the entry in Schedule 1 Part 1 of the Special Arrangement for ‘Epirubicin’ by removing a pharmaceutical benefit, which is the listed drug ‘Epirubicin’ in the form ‘Solution for injection containing epirubicin hydrochloride 10 mg in 5 mL’ with manner of administration ‘Injection/intravesical’ and brand ‘Pharmorubicin Solution’.

Item 8 amends the entry in Schedule 1 Part 1 of the Special Arrangement for ‘Epirubicin’ by removing a pharmaceutical benefit, which is the listed drug ‘Epirubicin’ in the form ‘Solution for injection containing epirubicin hydrochloride 20 mg in 10 mL’ with manner of administration ‘Injection/intravesical’ and brand ‘Pharmorubicin Solution’.

Item 9 amends the entry in Schedule 1 Part 1 of the Special Arrangement for ‘Irinotecan’ by removing a pharmaceutical benefit, which is the listed drug ‘Irinotecan’ in the form ‘I.V. injection containing irinotecan hydrochloride trihydrate 40 mg in 2 mL’ with manner of administration ‘Injection’ and brand ‘Camptosar’.

Item 10 amends the entry in Schedule 1 Part 1 of the Special Arrangement for ‘Mitozantrone’ by removing a pharmaceutical benefit, which is the listed drug ‘Mitozantrone’ in the form ‘Injection 10 mg (as hydrochloride) in 5 mL’ with manner of administration ‘Injection’ and brand ‘Pfizer Australia Pty Ltd’.

Item 11 amends the entry in Schedule 1 Part 1 of the Special Arrangement for ‘Mitozantrone’ by removing a pharmaceutical benefit, which is the listed drug ‘Mitozantrone’ in the form ‘Injection 25 mg (as hydrochloride) in 12.5 mL’ with manner of administration ‘Injection’ and brand ‘Pfizer Australia Pty Ltd’.

Item 12 amends the entry in Schedule 1 Part 1 of the Special Arrangement for ‘Oxaliplatin’ by removing a pharmaceutical benefit, which is the listed drug ‘Oxaliplatin’ in the form ‘Powder for I.V. infusion 100 mg’ with manner of administration ‘Injection’ and brand ‘Winthrop Oxaliplatin’.

Item 13 amends the entry in Schedule 1 Part 1 of the Special Arrangement for ‘Vincristine’ by removing a pharmaceutical benefit, which is the listed drug ‘Vincristine’ in the form ‘I.V. injection containing vincristine sulfate 1 mg in 1 mL’ with manner of administration ‘Injection’ and brand ‘Pfizer Australia Pty Ltd’.

Item 14 amends the entry in Schedule 2 of the Special Arrangement for ‘Ondansetron’ by removing a pharmaceutical benefit, which is the listed drug ‘Ondansetron’ in the form ‘I.V. injection 4 mg (as hydrochloride dihydrate) in 2 mL’ with manner of administration ‘Injection’ and brand ‘Pfizer Australia Pty Ltd’.

Item 15 amends the entry in Schedule 2 of the Special Arrangement for ‘Ondansetron’ by removing a pharmaceutical benefit, which is the listed drug ‘Ondansetron’ in the form ‘I.V. injection 8 mg (as hydrochloride dihydrate) in 4 mL’ with manner of administration ‘Injection’ and brand ‘Pfizer Australia Pty Ltd’.

Item 16 amends Schedule 3 of the Special Arrangement by removing the responsible person code ‘WA’ and the associated responsible person.

Items 17 to 20 amend the entry in Schedule 5 of the Special Arrangement by adding new details relevant to a special patient contribution for the listed drug ‘Bleomycin’ in the form ‘Powder for injection containing bleomycin sulfate 15,000 I.U.’ with manner of administration ‘Injection’ and brand ‘Bleo 15K’.

Statement of Compatibility with Human Rights

Prepared in accordance with Part 3 of the Human Rights (Parliamentary Scrutiny) Act 2011

National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2012 (No. 3)

This Legislative Instrument is compatible with the human rights and freedoms recognised or declared in the international instruments listed in section 3 of the *Human Rights (Parliamentary Scrutiny) Act 2011*.

Overview of the Legislative Instrument

The purpose of this legislative instrument, made under subsections 100(1) and 100(2) of the Act, is to amend the *National Health (Efficient Funding of Chemotherapy) Special Arrangement 2011* (PB 79 of 2011) (the Special Arrangement), to make changes to the special arrangement relating to the efficient funding of chemotherapy.

The Special Arrangement achieves greater efficiency in payment for the supply of injected or infused chemotherapy medicines (“chemotherapy pharmaceutical benefits”) to eligible patients being treated for cancer, to reflect the 2010 budget measure titled ‘Revised arrangements for the efficient funding of chemotherapy drugs’. This Special Arrangement also relates to the supply of medicines associated with the side-effects of cancer and cancer treatment (“related pharmaceutical benefits”) at certain public hospitals.

This Instrument:

- adds 2 new listed brands with the listed drug ‘Doxorubicin - Pegylated Liposomal’;
- removes 10 listed brands with the listed drugs ‘Carboplatin’, ‘Doxorubicin’, ‘Epirubicin’, ‘Irinotecan’, ‘Mitozantrone’, ‘Oxaliplatin’, ‘Vincristine’ and ‘Ondansetron’; and
- removes 3 pharmaceutical items with the listed drugs ‘Cisplatin’, ‘Doxorubicin’ and ‘Mitozantrone’.

This instrument also adds details relevant to the special patient contribution for a listed brand with the listed drug ‘Bleomycin’. This reflects a change made to the *National Health (Price and Special Patient Contribution) Determination 2010* (PB 109 of 2010).

This instrument also removes the responsible person code ‘WA’ and associated responsible person from the Special Arrangement.

Human rights implications

This legislative instrument engages Article 2 and 12 of the International Covenant on Economic, Social and Cultural Rights (ICESCR) by assisting with the progressive realisation by all appropriate means of the right of everyone to the enjoyment of the highest attainable standard of physical and mental health.

The Pharmaceutical Benefits Scheme (PBS) is a benefit scheme which assists with advancement of this human right by providing for subsidised access by patients to medicines. The recommendatory role of the Pharmaceutical Benefits Advisory Committee (PBAC) ensures that decisions about subsidised access to medicines on the PBS are evidence-based.

Conclusion

This Legislative Instrument is compatible with human rights because it advances the protection of human rights.

Felicity McNeill
First Assistant Secretary
Pharmaceutical Benefits Division
Department of Health and Ageing